Clinical trial
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
NCT00006475 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00006475 |
|---|---|
| Title | STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis |
| Official title | An Open-Label Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Blast Crisis |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Start date | Sep 1, 2000 |
| Primary completion | Dec 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Apr 26, 2004 |
| Last update posted | Feb 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: